

2-15-2021

Focused summary (2021) of updated guidelines for asthma management of adults and children ages 12+

Jennifer R. Mammen
University of Rhode Island, jmammen@uri.edu

Follow this and additional works at: <https://digitalcommons.uri.edu/oer-healthcare-asthma>

Recommended Citation

Mammen, Jennifer R., "Focused summary (2021) of updated guidelines for asthma management of adults and children ages 12+" (2021). *Asthma*. Paper 1.
<https://digitalcommons.uri.edu/oer-healthcare-asthma/1><https://digitalcommons.uri.edu/oer-healthcare-asthma/1>

This Report is brought to you for free and open access by the Open Educational Resources for Allied Healthcare Providers, Patients, and Communities at DigitalCommons@URI. It has been accepted for inclusion in Asthma by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.

Comparative Doses of Generic and Brand Name Inhaled Corticosteroids

Reassess uncontrolled asthma every 2 to 6 weeks until good control is achieved.

Use lowest dose needed to keep asthma well controlled. Consider step down if controlled for > 3 months

Focused Summary of Asthma Guidelines (2021) Pocket Guide for Clinicians For adults and children ages 12+ years

Generic name	Monotherapy Brand names	Brand names with LABA	Rx	ICS Dose	Dosing Ages 0-4 yrs	Dosing Ages 5-11 yrs	Dosing Ages 12+ yrs
Budesonide DPI +/- Formoterol	No LABA: Pulmicort	+ Formoterol: Symbicort	2x day	Low: Med: High:	Nebules: 0.25-0.5 mg >0.5-1 mg >1 mg:	- 180-360 mcg >360-720 mcg >720 mcg	- 180-540 mcg >540-1080 mcg >1080 mcg
Beclomethasone MDI	No LABA: Qvar		2x day	Low: Med: High:		80-160 mcg >160-320 mcg >320 mcg	80-240 mcg >240-480 mcg >480 mcg
Ciclesonide MDI	No LABA: Alvesco		2x day	Low: Med: High:		80-160 mcg >160-320 mcg >320 mcg	160-320 mcg >320-640 mcg >640 mcg
Flunisolide MDI	No LABA: Aerospan HFA		2x day	Low: Med: High:		160 mcg >160-480 mcg >480 mcg	320 mcg >320-640 mcg >640 mcg
Fluticasone Propionate MDI +/- Salmeterol	No LABA: Flovent HFA	+ Salmeterol: Advair HFA	2x day	Low: Med: High:	176 mcg >176-352 mcg >352 mcg	88-176 mcg >176-352 mcg >352 mcg	88-264 mcg >264-440 mcg >440 mcg
Fluticasone Propionate DPI +/- Salmeterol	No LABA: Flovent Diskus ArmonAir	+ Salmeterol: Advair Diskus Airduo Wixela	2x day	Low: Med: High:		100-200 mcg >200-400 mcg >400 mcg	100-300 mcg >300-500 mcg >500 mcg
Fluticasone Furoate DPI +/- Vilanterol	No LABA: Arnuity Ellipta	+ Vilanterol: *Breo *For 18+ yrs	1x day	Low: Med: High:			No low dose 100 mcg >100 mcg
Mometasone DPI +/- Formoterol	No LABA: Asmanex	+ Formoterol: Dulera	1x day or 2x day	Low: Med: High:		110 mcg 220-440 mcg >440 mcg	110-220 mcg >220-440 mcg >440 mcg

This brief clinical guide for the management of asthma is based on the Expert Panel Report 3 and 4 (draft) and GINA 2020 report and other current asthma research.

Use caution in assessing asthma symptoms. Many patients do not report "normal" symptoms and may ration inhaler use even when symptomatic. Consider using an approach like the following, and do not rely on frequency of SABA use as a conclusive measure of asthma control.

In general over the past 1 to 4 weeks:

1. How many days a week do you have any symptoms of recurrent coughing, wheezing, chest tightness/pain or repetitive throat clearing?
2. How many nights a week do you wake up from your asthma symptoms?
3. Has asthma limited your activity in any way lately?
4. What medication are you currently taking for your asthma and how do you take it?
5. How many times did you need to use your rescue inhaler for symptoms?
6. Do you always take your rescue inhaler when you have symptoms or do you wait?

COVID-19 guidance: avoid nebulizers or spirometry when possible to prevent aerosolizing virus.

Scan QR code for free patient friendly asthma guide for smartphone



Key points for patient and family education and self-management training:

1. Symptoms of asthma indicate "**swelling**" (inflammation) in lungs. Chronic inflammation causes "**scarring**" over time (remodeling). Emphasize symptoms > twice a week can lead to permanent scarring in the lungs.
2. Review medication types - Rescue and Control. Emphasize only control medication can "stop the scarring" and protect long term lung functioning. Control medication takes days to weeks to work. Explain that decreased swelling = fewer symptoms = less need for/dependence on SABA over time.
3. Emphasize that asthma inhalers only work if taken correctly - "Get it in and keep it in." It is critical to explain, model, and require return demonstration of inhaler technique over multiple visits. Use spacer for all ages.
4. Help establish an easy to follow routine: Keep inhalers in high visibility/access locations (ex. with toothbrush).
5. Encourage using a digital peak flow meter to help patient understand effect of inflammation in the lungs.

Help us help you: For additional updated copies of this guide, scan the QR code to download, or go to: <https://digitalcommons.uri.edu/oer-healthcare-asthma/1>



Intermittent Asthma

Management of Persistent Asthma in Individuals Ages 12 Years and Older

Consult with asthma specialist if Step 4 or higher is needed.

Reassess uncontrolled asthma every 2 to 6 weeks until good control is achieved.

ICS = inhaled corticosteroid (ICS+LABA indicates combined/concomitant use of both medications)
 LABA = long acting beta agonist
 LAMA = long acting muscarinic agonist
 LTRA = leukotriene receptor agonist
 OCS = oral systemic corticosteroid
 SABA = short acting beta agonist

STEP 5+

Severe Persistent

STEP 4

Moderate Persistent

STEP 3

Moderate Persistent

STEP 2

Mild Persistent

STEP 1

Intermittent

Preferred (EPR4):

- PRN SABA

Preferred options (GINA):

- PRN ICS+LABA
- PRN low-dose ICS taken when SABA used

For acute symptoms:
 2-8 puffs albuterol or 1 nebulizer; up to 3 treatments @ 20 minute intervals PRN; may need OCS

Preferred EPR4 & GINA:

- Daily low-dose ICS and PRN SABA
- PRN low-dose ICS taken when SABA used

Preferred option (GINA):

- PRN ICS+LABA

Alternative options:

- Daily LTRA and PRN SABA

Preferred EPR4 & GINA:

- Low-dose *SMART

Alternative options:

- Daily medium-dose ICS and PRN SABA
- Daily low-dose ICS+LABA and PRN SABA
- Daily low-dose ICS+LAMA and PRN SABA
- Daily low-dose ICS and LTRA and PRN SABA

Preferred EPR4 & GINA:

- Medium-dose *SMART

Alternative options:

- Daily medium-dose ICS+LABA and PRN SABA
- Daily higher-dose ICS+LABA and PRN SABA
- Daily medium-dose ICS+LAMA and PRN SABA

Preferred EPR4 & GINA:

- Daily medium to high dose ICS+LABA and LAMA and PRN SABA

Alternative options:

- Daily high-dose ICS+LABA and PRN SABA
- Daily high-dose ICS and LTRA and PRN SABA
- For other options: see guidelines

FDA issued Boxed Warning for montelukast in March 2020

***SMART - Single Maintenance and Reliever Therapy (currently off label in U.S.):** Preferred for all patients at step 3 to 4;

SMART is combined ICS + formoterol (LABA) given daily for control PLUS as needed for symptoms (up to 12 total puffs per day for > 12 years age).

Classifying Asthma Severity in Individuals Ages 12 Years and Older

Assess severity BEFORE start of controller therapy based on symptoms, OR estimated based on level of stepwise therapy PLUS current level of control.

Intermittent

Symptoms:

Days: 2 days/wk or less
Wake up: <2/month
Activity: no limitations
PEF or FEV1: > 80%
SABA: ≤2 time/week

Well controlled

Mild Persistent

Symptoms:

Days: >2 days/wk, not daily
Wake up: 3 - 4/month
Activity: minor limitations
PEF or FEV1: > 80%
SABA: >2 time/week

Not well controlled (NWC)

Moderate Persistent

Symptoms:

Days: everyday (but not throughout the day)
Wake up: >1/week, but not nightly; *(≥4/week is VPC)
Activity: some limitations
PEF or FEV1: 60 - 80%
SABA: Daily

oral/systemic steroid use > 1 x year

Severe Persistent

Symptoms:

Days: throughout the day
Wake up: often 7x week
Activity: extremely limited
PEF or FEV1: < 60%
SABA: Several times daily

Very poorly controlled (VPC)

Assess and document BOTH severity and control at every visit. Control corresponds with highest level of current symptoms in any symptom box.

Classifying Asthma Control in Individuals Ages 12 Years and Older

Version date: 2/19/2021